News and Blog
Welcome to your information hub to keep up to date with our latest news, product launches, industry insights, case studies and much more.
View all blogs:
Croda welcomes Thomas Riermeier as new President of Life Sciences
Croda International Plc, the company that uses smart science to create ingredients and technologies that improve lives, today announces that Dr. Thomas Riermeier has been appointed as the new...
Croda Pharma launches a new bioprocessing solution for shear stress in mammalian cell culture
Croda Pharma has announced the launch of Super Refined™ Poloxamer 188, an innovative bioprocessing solution developed to meet the increasing demands of biopharmaceutical development.
Announcing Avanti Research - a Croda brand
Avanti Polar Lipids, a global leader in lipids, has announced its renewed offering for researchers and its transformation to Avanti Research.
EXCLUSIVE WHITEPAPER: Next-generation Triton™ X-100 replacements for pharmaceutical bioprocessing
Triton™ X-100 (tert-octyl phenyl ethoxylate) is used extensively in the manufacture of biologics, plasma-derived products and cell and gene therapies (CGTs). This non-ionic detergent is used because...
.png?w=768&la=es-MX&focalpointcrop=1&xratio=0&yratio=0&hash=B301C96CCD8120143037862319E11640)
Veterinary vaccines - solutions for an ongoing challenge...
Growth in the veterinary pharmaceutical industry continues to be driven by increasing pet ownership globally and the rising demand for veterinary vaccines to prevent the risk of zoonotic diseases in...
.png?w=768&la=es-MX&focalpointcrop=1&xratio=0&yratio=0&hash=8D4A4716F7413779B7F202A086E07C9F)
QbD Formulation Development
Formulation development is a pivotal stage in the life cycle of a therapeutic drug product, it can be the make or break of it. The goal of formulation development is to convert active substance (drug...
Croda joins CGT Catapult consortium to improve AAV formulation
The Cell and Gene Therapy Catapult (CGT Catapult) has established a cross-industry consortium to improve the understanding and process optimisation of adeno-associated virus (AAV) formulation.
Croda Foundation announces it has sustainably improved the lives of 22.8 million people – exceeding its 2030 target.
Croda Foundation announces it has sustainably improved the lives of 22.8 million people –exceeding its 2030 target.
Partnership agreement between Croda and AAHI to drive innovation in vaccine development
19 March 2024: Croda International Plc (Croda) and The Access to Advanced Health Institute (AAHI) are pleased to announce today the signing of a partnership agreement around innovation and development...
Specializing in specific enhancement technologies
Croda Pharma specializes in four technologies aimed at improving bioavailability and solubility. Find out more!
Concerns about Triton™ X-100 have been an ongoing discussion across multiple regulatory authorities around the world
Triton™ X-100, a non-ionic surfactant with a hydrophilic polyethylene oxide chain and a hydrophobic aromatic group1, has found widespread use in the biopharmaceutical industry with applications...
“Close the Care Gap” – World Cancer Day 2024
We are proud to continue supporting the development of cancer treatments, and on this World Cancer Day, recognise the importance of innovation and science to cure and treat those diagnosed. Together,...
Spotlight on Kritika Bajaj
Highlighting the scientists and teams who are involved in our latest product launch, Virodex™, replacements for Triton™ X-100, we sat down with Kritika Bajaj and asked her about her involvement around...
Croda’s response to Sustainable Markets Initiative for supplier sustainability targets
The recent open letter from the Sustainable Markets Initiative Health Systems Task Force called for Healthcare supply chains to become greener, more efficient and circular and set out a series of...
Sustainability for vaccines: Decarbonisation of one of our key sites
Sustainability is often defined as meeting the needs of those alive today without compromising the ability of future generations to meet their needs. It is a long-term goal that covers three pillars:...
A powerful match - celebrating three years of Croda Pharma and Avanti
Today marks three years since we acquired Avanti Polar Lipids. During the COVID-19 pandemic, it became clear that the combination of Avanti's lipid expertise and our manufacturing scale-up capability...
Introducing new bioprocessing solutions to replace banned materials
We have introduced a critical range of new bioprocessing detergents optimised for viral inactivation and cell lysis. The company’s new product range, Virodex™, offers an answer to the key market need...
Cholesterol: enhancing stability and efficacy in lipid-based drug delivery
Cholesterol, a key component in lipid-based drug delivery systems, provides structural support and stability, enhances the efficiency of intracellular delivery and gene transfection.
Acquisition of Solus Biotech expands specialised Pharma business in Asia
05 July 2023: Croda International Plc (‘Croda’) announced that it has acquired Solus Biotech, a global leader in premium, biotechnology-derived materials, from Solus Advanced Materials
Acquisition of Solus Biotech strengthens Croda Pharma
On 04 July Croda successfully completed the acquisition of Solus Biotech, an innovative biotechnology company with over three decades of industry experience.
Lets connect...
Register to the mailing list to unlock:
- First access to new products, new data and exclusive literature
- Whitepapers and thought provoking content
- Special offers on conference and exhibition passes when available
- Invitations to invite only Croda Pharma events.